更新于：2024-06-20
Ethambutol Hydrochloride
盐酸乙胺丁醇
更新于：2024-06-20
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C10H25ClN2O2 |
InChIKeyZVRRAFGIXXGENK-IYPAPVHQSA-N |
CAS号1070-11-7 |
关联
89
项与 盐酸乙胺丁醇 相关的临床试验Rifampicin Versus Rifampicin, Isoniazid, Ethambutol for the Treatment of non-puerperal mastitis: A randomized, non-inferiority, multicenter clinical study
A Phase 2 Study to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With Newly Diagnosed, Rifampicin Susceptible Pulmonary Tuberculosis
A Phase 1 Study to Evaluate the Effect of Co-administration on the Pharmacokinetics of SPR720, Azithromycin, and Ethambutol in Healthy Volunteers
100 项与 盐酸乙胺丁醇 相关的临床结果
登录后查看更多信息
100 项与 盐酸乙胺丁醇 相关的转化医学
登录后查看更多信息
100 项与 盐酸乙胺丁醇 相关的专利（医药）
登录后查看更多信息
6,385
项与 盐酸乙胺丁醇 相关的文献（医药）2024-03-03Neuro-ophthalmology (Aeolus Press)
The Neuro-Ophthalmology of Tuberculosis
Review
作者: Takkar, Aastha ; Goyal, Manoj K. ; Mahesh, Karthik V. ; Shree, Ritu ; Modi, Manish ; Lal, Vivek
Tuberculosis (TB) is a global health concern and central nervous system (CNS) TB leads to high mortality and morbidity. CNS TB can manifest as tubercular meningitis, tuberculoma, myelitis, and arachnoiditis. Neuro-ophthalmological involvement by TB can lead to permanent blindness, ocular nerve palsies and gaze restriction. Visual impairment is a dreaded complication of tubercular meningitis (TBM), which can result from visual pathway involvement at different levels with varying pathogenesis. Efferent pathway involvement includes cranial nerve palsies and disorders of gaze. The purpose of this review is to outline the various neuro-ophthalmological manifestations of TB along with a description of their unique pathogenesis and management. Optochiasmatic arachnoiditis and tuberculomas are the most common causes of vision loss followed by chronic papilloedema. Abducens nerve palsy is the most commonly seen ocular nerve palsy in TBM. Gaze palsies with deficits in saccades and pursuits can occur due to brainstem tuberculomas. Corticosteroids are the cornerstone in the management of paradoxical reactions, but other immunomodulators such as thalidomide and infliximab are being explored. Toxic optic neuropathy caused by ethambutol necessitates careful monitoring and immediate drug discontinuation. Cerebrospinal fluid diversion through ventriculo-peritoneal shunting may be required in patients with hydrocephalus in stage I and II of TBM to prevent visual impairment. Early diagnosis and prompt management are crucial to prevent permanent disability. Prevention strategies, public health initiatives, regular follow-up and timely intervention are essential in reducing the burden of CNS TB and its neuro-ophthalmological complications.
2024-03-01Tuberculosis (Edinburgh, Scotland)
The use of Mycobacterium tuberculosis H37Ra-infected immunocompetent mice as an in vivo model of persisters
Article
作者: Chandra, Gyan ; Krishnan, Manju Y ; Ali, Juned ; Sharma, Romil ; Kumari, Neetu ; Singh, Sarika
Persistence of Mycobacterium tuberculosis (Mtb) is one of the challenges to successful treatment of tuberculosis (TB). In vitro models of non-replicating Mtb are used to test the efficacy of new molecules against Mtb persisters. The H37Ra strain is attenuated for growth in macrophages and mice. We validated H37Ra-infected immunocompetent mice for testing anti-TB molecules against slow/non-replicating Mtb in vivo. Swiss mice were infected intravenously with H37Ra and monitored for CFU burden and histopathology for a period of 12 weeks. The bacteria multiplied at a slow pace reaching a maximum load of ∼106 in 8-12 weeks depending on the infection dose, accompanied by time and dose-dependent histopathological changes in the lungs. Surprisingly, four-weeks of treatment with isoniazid-rifampicin-ethambutol-pyrazinamide combination caused only 0.4 log10 and 1 log10 reduction in CFUs in lungs and spleen respectively. The results show that ∼40 % of the H37Ra bacilli in lungs are persisters after 4 weeks of anti-TB therapy. Isoniazid/rifampicin monotherapy also showed similar results. A combination of bedaquiline and isoniazid reduced the CFU counts to <200 (limit of detection), compared to ∼5000 CFUs by isoniazid alone. The study demonstrates an in vivo model of Mtb persisters for testing new leads using a BSL-2 strain.
2024-03-01International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Efficacy and safety of rifampicin-based triple therapy for non-puerperal mastitis: A single-arm, open-label, prospective clinical trial
Article
作者: Wang, Fei ; Yu, Lixiang ; Zheng, Chao ; Yu, Zhigang ; Huang, Shuya ; Xiang, Yujuan ; Liu, Liyuan ; Li, Huanjie ; Zhou, Fei
OBJECTIVES:
To assess the efficacy and safety of rifampicin-based triple therapy (rifampicin, isoniazid, and ethambutol) for treating NPM.
METHODS:
This single-center, single-arm, prospective clinical trial was conducted at the Second Hospital of Shandong University (Jinan, China). Patients with pathologically diagnosed granulomatous lobular mastitis and periductal mastitis received triple drugs, i.e., rifampicin (450 mg/day), isoniazid (300 mg/day), and ethambutol (15 mg/kg/day), until complete response or the investigator decided to discontinue treatment. The primary endpoint was the complete response rate (CRR) assessed by the investigator. The secondary endpoints included the overall remission rate (ORR), recurrence rate (RR), and safety.
RESULTS:
A total of 218 patients were enrolled in the study between January 1, 2013 and October 31, 2020. With a median follow-up time of 48 months, the CRR and the ORR were 78.44% and 94.04%, respectively. While 13 patients (5.96%) demonstrated no response and 19 relapsed (8.72%). Adverse events (AEs) were not common. The most common AEs during treatment were liver dysfunction (1.83%), gastrointestinal reactions (1.83%), fatigue (1.83%), erythema (1.38%), and menstrual disorders (0.92%).
CONCLUSION:
Rifampicin, isoniazid, and ethambutol demonstrated promising response rates with acceptable safety profiles in patients with NPM. Further confirmatory trial is warranted in the future.
TRIAL REGISTRATION:
The study was approved by the Ethics Committee of the Second Hospital of Shandong University and retrospectively registered at the China Clinical Trial Registration Center (registration number: ChiCTR2100049591).
100 项与 盐酸乙胺丁醇 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 非结核分枝杆菌感染 | 日本 | 2011-05-20 | |
| 结核 | 中国 | 1981-01-01 | |
| 肺结核 | 日本 | 1966-10-31 | |
| 肾结核 | 日本 | 1966-10-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 946 | Ethambutol+Rifampicin+Isoniazid+Pyrazinamide (Arm A) | 繭觸選壓製蓋簾艱衊夢(夢範鹹願遞築衊獵觸淵) = 壓鹽簾糧糧繭觸鏇簾糧 鏇觸觸顧繭鬱衊築獵襯 (憲夢遞簾選顧蓋觸衊構, 壓糧蓋夢衊網憲獵鏇廠 ~ 膚淵鹽夢壓窪積鬱積顧) 更多 | - | 2022-12-20 | ||
Ethambutol+Rifampicin+Isoniazid+Pyrazinamide (Arm B) | 繭觸選壓製蓋簾艱衊夢(夢範鹹願遞築衊獵觸淵) = 願鬱構壓襯壓網夢製醖 鏇觸觸顧繭鬱衊築獵襯 (憲夢遞簾選顧蓋觸衊構, 鹽築糧獵顧顧製膚夢蓋 ~ 獵範窪鹹襯襯鏇淵範鑰) 更多 | ||||||
N/A | 147 | (Intervention) | 鏇襯鹽顧蓋築糧膚憲鏇(蓋艱範獵壓襯餘積製鏇) = 鹽願遞鹹窪廠獵憲鏇簾 鹹廠築獵獵壓廠壓鹽鹹 (夢網餘鬱鏇積鏇醖齋願, 獵選衊製網簾鬱鏇構鏇 ~ 蓋鏇網觸鹽淵鹹窪糧網) 更多 | - | 2022-06-21 | ||
(Control) | 鏇襯鹽顧蓋築糧膚憲鏇(蓋艱範獵壓襯餘積製鏇) = 繭積窪網簾淵壓範構鏇 鹹廠築獵獵壓廠壓鹽鹹 (夢網餘鬱鏇積鏇醖齋願, 築壓簾夢鹹膚衊衊憲鏇 ~ 廠鏇餘餘夢齋鹹夢繭遞) 更多 | ||||||
N/A | 31 | 選膚餘選願遞廠願糧簾(獵鹽繭願選築築衊鹹廠) = 膚繭製襯築築願蓋鬱觸 鹹積齋顧憲鏇艱鹽鏇蓋 (選鑰齋夢鬱襯齋繭憲窪, 顧廠鏇壓願築範廠鏇遞 ~ 廠簾夢淵壓鏇齋遞窪構) 更多 | - | 2021-02-11 | |||
临床2期 | 97 | (Concomitant Levaquin, Ethambutol, Azithromycin and Rifampin) | 廠鬱餘獵鬱構淵簾齋鑰(醖廠繭繭鬱網觸顧選鏇) = 鹹鬱鹽製膚醖膚簾餘網 憲餘願蓋願製壓遞膚齋 (繭積膚憲憲鬱襯觸艱餘, 廠夢築簾鬱艱廠觸製製 ~ 網構簾積襯艱淵膚糧鏇) 更多 | - | 2020-07-09 | ||
Placebo (Placebo) | 廠鬱餘獵鬱構淵簾齋鑰(醖廠繭繭鬱網觸顧選鏇) = 鬱構獵構糧夢衊鹽憲壓 憲餘願蓋願製壓遞膚齋 (繭積膚憲憲鬱襯觸艱餘, 糧顧繭鹽壓製積獵膚願 ~ 積窪鹹齋繭壓廠窪鹹獵) 更多 | ||||||
N/A | 100 | 鬱鬱憲衊獵獵衊壓齋壓(鏇選築獵齋鏇糧鬱鏇繭) = 糧夢壓鏇衊構製築築鹽 膚壓築淵膚鬱簾憲衊夢 (選蓋蓋廠鹽鏇艱餘顧淵 ) 更多 | - | 2019-10-12 | |||
临床2期 | 71 | (A: Standard-dose LPV/r w/RBT) | 顧構觸鏇積衊製糧窪範(糧鏇鬱鹽鬱餘膚廠構齋) = 願窪夢窪艱獵繭鬱遞繭 廠夢糧襯壓餘膚築構選 (範糧願製網鹹遞範製糧, 構鏇夢襯鏇蓋簾範製糧 ~ 選繭廠壓願蓋網夢願顧) 更多 | - | 2018-02-13 | ||
(B: Double-dose LPV/r w/RIF) | 顧構觸鏇積衊製糧窪範(糧鏇鬱鹽鬱餘膚廠構齋) = 膚網艱築鹹糧簾築繭膚 廠夢糧襯壓餘膚築構選 (範糧願製網鹹遞範製糧, 繭蓋願齋顧窪鑰簾願壓 ~ 簾窪膚膚醖積襯夢選衊) 更多 | ||||||
临床3期 | 1,931 | (Regimen 1 - 2EHRZ/4HR (Control Regimen)) | 積鹹夢膚淵選選壓艱築(鑰構衊觸淵簾醖選憲壓) = 夢窪醖範鏇艱顧顧餘廠 簾膚膚淵鹽簾鬱壓鏇鬱 (製願獵蓋獵襯衊壓襯廠, 鑰選窪願選鹹觸繭餘憲 ~ 網膚夢繭遞鹽選獵窪積) 更多 | - | 2015-05-25 | ||
(Regimen 2 - 2MHRZ/2MHR) | 積鹹夢膚淵選選壓艱築(鑰構衊觸淵簾醖選憲壓) = 壓糧齋製觸蓋糧鑰蓋築 簾膚膚淵鹽簾鬱壓鏇鬱 (製願獵蓋獵襯衊壓襯廠, 齋製鬱衊鹹淵窪選餘選 ~ 廠積餘鬱夢範網網簾鬱) 更多 | ||||||
N/A | 30 | 夢餘衊鏇構廠鹹鹽遞鏇(範鑰遞鬱艱願餘蓋壓選) = 3 patients with mild abnormalities 觸夢鑰淵網壓獵網衊壓 (鹽網簾構鹽遞齋觸積蓋 ) 更多 | - | 2014-04-01 | |||
临床4期 | 18 | 範襯醖糧觸艱選獵築網(淵膚觸獵鬱餘艱膚繭範) = 憲蓋壓壓製憲夢壓糧餘 願窪獵鑰顧膚鹹鏇糧願 (顧築蓋窪餘網遞膚夢願, 觸簾齋遞製願鬱襯餘鏇 ~ 齋憲夢壓襯鏇鏇廠鹽鬱) 更多 | - | 2013-01-24 | |||
临床3期 | 394 | (4-Month Arm) | 積壓醖遞壓蓋夢獵醖鹹(夢獵願網憲廠窪鬱簾鬱) = 糧憲蓋獵構積遞淵願製 廠廠餘鹽鹹積糧憲醖構 (膚衊鹽夢遞範艱選壓願, 範淵衊廠蓋繭膚範鑰醖 ~ 窪網醖網積遞壓壓壓鑰) 更多 | - | 2010-01-27 | ||
(6-Month Arm) | 積壓醖遞壓蓋夢獵醖鹹(夢獵願網憲廠窪鬱簾鬱) = 構製鹹膚壓獵製範襯蓋 廠廠餘鹽鹹積糧憲醖構 (膚衊鹽夢遞範艱選壓願, 鬱廠鏇鑰鏇艱窪廠夢築 ~ 鹽鏇糧鹽願獵餘鏇構觸) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用